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Worldwide the rising incidence of cancer is attributed to ageing populations, environmental and 
lifestyle factors, and increased cancer surveillance. Cancer surveillance leads to increased early 
detection of indolent cancers and in some cases to cancer ‘overdiagnosis’1. In the thyroid the 
increased incidence of thyroid cancer and cancer detection is primarily due to widespread use of 
thyroid ultrasound2. This excess of newly diagnosed thyroid cancers occurs almost entirely because 
of greater detection papillary thyroid cancers, a tumour which under the microscope shows a 
characteristic papillary growth pattern together with typical nuclear features. Follicular variant of 
papillary carcinoma (FVPTC) is one of two major subtypes of papillary thyroid cancer. The 
encapsulated type of follicular variant of papillary carcinoma (eFVPTC), a tumour which under the 
microscope shows no invasion of surrounding thyroid, blood vessels, or lymphatics has increased in 
incidence 2 to 3 times over the last 20 to 30 years. eFVPTC is now estimated to comprise 
approximately 10 to 20% of all newly diagnosed thyroid cancers in Europe and North America3, 4. 
eFVPTC is challenging to diagnose and controversial because the tumour does not show invasion and 
so the diagnosis rests entirely on the ability of the pathologist to identify the characteristic papillary 
nuclear features despite the microscopic features of eFVPTC being very subjective5,6,7. Although 
eFVPTC thyroid cancers behave in a very indolent fashion patients with eFVPTC are often treated in a 
similar way to those patients with more aggressive thyroid tumours that show invasion, for example 
with completion thyroidectomy, that is removal of the whole thyroid gland as a second operation 
followed by radioiodine for thyroid gland ablation. 
In the last few weeks, a large international working group of thyroid pathologists and clinical thyroid 
experts has published the results of an international collaboration aimed to re-evaluate the 
pathological criteria and clinical behaviour of  eFVPTC. The study shows that the pathological 
diagnostic criteria for FVPTC can now be standardized.  Most importantly, when eFVPTC were 
diagnosed based on these criteria and the tumours were non-invasive, none of 109 patients 
followed on average for 14 years developed any adverse events despite the presence of nuclear 
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features of papillary carcinoma.  Based on this outcome, some FVPTC thyroid tumours which until 
just few months ago would have been diagnosed as ‘carcinoma’ should no longer be regarded as 
‘cancers’ but rather as a tumour with a very low risk of malignancy, designated as ‘non-invasive 
follicular thyroid neoplasm with papillary like nuclei, a NIFTP’ 8.  There are also now a series of other 
articles on NIFTP exploring the effects on rates of pathological diagnosis of thyroid cancer 9 and FNA 
cytology diagnosis 10,11  of cancer in thyroid nodules and the implications for patients.  Pre-operative 
diagnosis of thyroid nodules using thyroid FNA cytology will change as the positive predictive value 
(PPV) - the likelihood that a diagnosis of malignancy is indeed a true malignant for a Bethesda Class 
VI thyroid FNA (in the UK these are termed Thy 5) is predicted to fall from 99% to around 95% with a 
similar reduction in the PPV for malignancy of Bethesda Class V , IV, and III FNA’s, -in the UK these 
categories are broadly equivalent to Thy 4, Thy 3F and Thy 3A thyroid FNA’s. Despite this 
reclassification, it is important to stress that NIFTP is still a tumour driven by potent oncogenes, such 
as RAS, and has to be surgically excised in order to rule out invasion, which separate these tumours 
from invasive PTC. Therefore, NIFTP is a surgical disease, but removal by lobectomy should be a 
curative and these patients will not benefit from completion total thyroidectomy and radioiodine 
therapy. Cytologists and multi-disciplinary teams will have to adjust their management strategies to 
accommodate the NIFTP diagnosis.  
 
There are undoubtedly other areas in cancer diagnosis where the terminology ‘cancer’ has persisted 
over time and where terminology change is perhaps required e.g. in the breast for ‘lobular in situ 
neoplasia’ rather than ‘lobular carcinoma in situ’.  
This study demonstrates the value of international collaboration in applying evidence based 
medicine including molecular tumour subtyping to develop new diagnostic thresholds for disease, 
including cancers,  in response to increased cancer incidence due to the worldwide ageing of 
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populations in developed countries and increased public awareness and demand for both 
appropriate and cost effective healthcare. 
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